Clinical Trials Logo

Filter by:
NCT ID: NCT02552940 Completed - Clinical trials for Rheumatoid Arthritis

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Start date: October 31, 2015
Phase:
Study type: Observational

This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.

NCT ID: NCT02552914 Completed - Clinical trials for Sexually Transmitted Diseases, Bacterial

Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs

Colli-Pee
Start date: September 2015
Phase:
Study type: Observational

Study objectives: - To evaluate the usability of the Colli-PeeTM device to collect first-void urine for nucleic acid detection of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalium. - To collect feedback on the easiness of use and the willingness of future use of the Colli-PeeTM device.

NCT ID: NCT02552485 Completed - Clinical trials for Atrial Septal Defects

Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions

Start date: January 2015
Phase: N/A
Study type: Observational

Prospective, monocentric study for the evaluation of latent pulmonary arterial hypertension in patients with congenital shunt lesions lost to follow-up. Lost to follow-up is defined as latest clinical control ≥ 5 years.

NCT ID: NCT02552238 Completed - Clinical trials for Coronary Artery Disease

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

Start date: October 12, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.

NCT ID: NCT02552121 Completed - Bladder Cancer Clinical Trials

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Start date: November 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.

NCT ID: NCT02551159 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

KESTREL
Start date: October 15, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.

NCT ID: NCT02550639 Completed - Clinical trials for Kidney Transplantation

Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant

RESPECT
Start date: February 2014
Phase: Phase 4
Study type: Interventional

The aim of this prospective, randomized study is to assess a subject's immunological status against hCMV before kidney transplantation by an hCMV-specific interferon (INF)-γ ELISPOT technique confirming previous results and establishing their statistical validity in order to determine whether this test could be used routinely in clinical practice to assess the risk of developing hCMV infection after renal transplantation and, ultimately, identify the most effective individual antiviral therapeutic strategy against hCMV.

NCT ID: NCT02550535 Completed - Clinical trials for Myelodysplastic Syndromes (MDS)

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II trial to determine safety, clinical efficacy and feasibility of a gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Patient's white blood cells (T cells) will be modified by transferring a gene which enables them to make a new T cell receptor (TCR) that can recognize fragments of a protein called WT1 (Wilms' tumour 1) which is present at abnormally high levels on the surface of myelodysplastic and leukaemic cells. In this trial, approximately 25 participants with an Human Leukocyte Antigen A2 (HLA-A*0201) tissue type who have failed to achieve or maintain an IWG defined response following hypomethylating agent therapy will be recruited.

NCT ID: NCT02549001 Completed - Onychomycosis Clinical Trials

Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis

Start date: August 20, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether P-3058 nail solution is a safe and effective treatment for onychomycosis.

NCT ID: NCT02547974 Completed - Clinical trials for Respiratory Disorders

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.

Start date: August 31, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK Biologicals' GSK3277511A vaccine in adults